Patents by Inventor Susan Kautz

Susan Kautz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Citrate buffered VEGF antagonist formulations
    Patent number: 11806398
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF Antagonist Formulations
    Publication number: 20210393778
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 6, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210393530
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 23, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210252105
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 5, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210252147
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 4, 2021
    Publication date: August 19, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF Antagonist Formulations
    Publication number: 20210077624
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 17, 2020
    Publication date: March 18, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Formulations of VEG antagonist fusion proteins and method of manufacturing them
    Patent number: 10857231
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: December 8, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS
    Publication number: 20190388539
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 26, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Method of manufacturing VEGF antagonist fusion proteins
    Patent number: 10406226
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20170360930
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • VEGF specific fusion protein antagonist formulations
    Patent number: 9636400
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: May 2, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Daniel B. Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20170073407
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 16, 2017
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Stable VEGF antagonist formulations
    Patent number: 9511140
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: December 6, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20160244504
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: May 10, 2016
    Publication date: August 25, 2016
    Inventors: Daniel B. DIX, Kelly FRYE, Susan KAUTZ
  • Stable liquid formulations of dimer VEGF antagonists
    Patent number: 9416167
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: August 16, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20160175439
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: March 8, 2016
    Publication date: June 23, 2016
    Inventors: Daniel DIX, Kelly FRYE, Susan KAUTZ
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20150079087
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: Daniel DIX, Kelly FRYE, Susan KAUTZ
  • Stable liquid VEGF antagonist formulations
    Patent number: 8921316
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 4, 2013
    Date of Patent: December 30, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • Stable liquid VEGF antagonist formulations
    Patent number: 8710004
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: April 29, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Kelly Frye, Susan Kautz
  • VEGF ANTAGONIST FORMULATIONS
    Publication number: 20130261056
    Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 3, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel DIX, Kelly FRYE, Susan KAUTZ